Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$0.32 - $0.67 $13,897 - $29,097
-43,429 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.72 - $2.93 $90,275 - $367,369
-125,382 Reduced 74.27%
43,429 $31,000
Q4 2021

Jan 20, 2022

BUY
$2.26 - $3.34 $381,512 - $563,828
168,811 New
168,811 $382,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $305M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Ardent Capital Management, Inc. Portfolio

Follow Ardent Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ardent Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ardent Capital Management, Inc. with notifications on news.